Clinical trials: copd or chronic obstructive
Asthma
Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics
This study is designed to evaluate the repeat-dose safety and effectiveness of a bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11 years with asthma.
- Trial name
- NCT00308685
- Testing
- Albuterol
- Where
- 14 sites in United States
- Volunteers
- 95 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Graft Versus Host Disease
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
This study was a single arm, open label, multicenter phase Ib / II trial in subjects with glucocorticoid refractory / dependent moderate to severe cGVHD.The trial consisted of two phases: phase I for the dose exploration and…
- Trial name
- NCT04944043
- Testing
- TQ05105 Tablet
- Where
- 12 sites in China
- Volunteers
- 45 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients
This is a descriptive observational open non-comparative study of the safety and efficacy of tiotropium inhalation capsule given at 18mcg once a day for 30 days among Korean patients with COPD.
- Trial name
- NCT00620516
- Where
- 71 sites in South Korea
- Volunteers
- 3,008 people
- Sponsor
- Boehringer Ingelheim
COPD
Patient's Perception in Symptoms Related to Morning Activity Based on Chronic Obstructive Lung Disease
The aim of this study is to assess the perception of chronic obstructive pulmonary disease (COPD) patients in symptoms related to morning activities.
- Trial name
- SYMBOL (NCT00894426)
- Where
- 3 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Ipratropium Bromide in Peri-Operative COPD
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-centre trial.The trial aims to evaluate efficacy of nebulized ipratropium bromide in Chinese peri-operative patients with COPD under general…
- Trial name
- NCT01943552
- Testing
- ipratropium bromide
- Where
- 9 sites in China
- Volunteers
- 192 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
The purpose of this extension study is to evaluate the long-term safety, tolerability, and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT00970268
- Testing
- Aclidinium bromide
- Where
- 83 sites in United States, Canada
- Volunteers
- 291 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic Treatment
The study will assess the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) stage III and IV who will self administer the AlphaCore stimulation three times a day over a course of 2 months.
- Trial name
- NCT01679314
- Testing
- AlphaCore device
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- ElectroCore INC
COPD
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI
Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003 and…
- Trial name
- NCT02347085
- Testing
- GFF MDI (PT003)
- Volunteers
- 43 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects
A study to assess the pharmacokinetics and safety of two doses of PT010 and a single dose of PT003 in healthy Chinese adult subjects
- Trial name
- NCT03075267
- Testing
- PT010 (BGF MDI) 320/14.4/9.6 µg, PT010 (BGF MDI) 160/14.4/9.6 µg, PT003 (GFF MDI) 14.4/9.6 µg
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is an open-label, Phase 3, long-term safety extension study including participants of previous lunsekimig clinical trials with inadequately controlled chronic obstructive pulmonary disease (COPD ) characterized by an…
- Trial name
- COLOSSUS (NCT07793409)
- Testing
- Lunsekimig
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 1,508 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD
The primary objective of this trial is to establish superiority of the once-daily Tiotropium plus Salmeterol Inhalation Powder in daytime lung function response and non-inferiority in night-time lung function response over the…
- Trial name
- NCT00662792
- Testing
- Tiotropium (Tio18GEL), Salmeterol MDPI (Salm50DPI), Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)
- Where
- 12 sites in Germany
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
Bronchitis, Chronic, Pulmonary Disease, Chronic Obstructive
Mucolytic Effectiveness of Tacholiquine ® in Chronic Bronchitis
The purpose of this study is to evaluate the mucolytic activity of Tacholiquine® compared to saline (0.9%) in chronic bronchitis patients.
- Trial name
- Tacho-COPD (NCT02515799)
- Testing
- Tacholiquine
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- bene-Arzneimittel GmbH
Chronic Obstructive Pulmonary Disease (COPD)
Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation
The purpose of this study is to evaluate the safety of Targeted Lung Denervation Therapy (or TLD TherapyTM) in patients suffering from COPD.
- Trial name
- IPS-I (NCT01483534)
- Testing
- TLD Therapy (IPS SystemTM)
- Where
- 3 sites in Netherlands, South Africa
- Volunteers
- 22 people
- Sponsor
- Nuvaira, Inc.
COPD
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
- Trial name
- NCT00215436
- Testing
- Formoterol Fumarate
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Dey
Dyspnea
Vibration Response Imaging (VRI) in Dyspnea Patients Presenting to the ED
For the patient with acute dyspnea in the ED, early differentiation between CHF and non-CHF causes is essential for proper management.
- Trial name
- NCT01206621
- Where
- 8 sites in United States, Israel
- Volunteers
- 530 people
- Sponsor
- Deep Breeze
Pulmonary Disease, Chronic Obstructive, COPD
Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)
The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with COPD.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00396604
- Testing
- indacaterol maleate
- Where
- Belgium
- Volunteers
- 51 people
- Sponsor
- Novartis
Emphysema, Acute Respiratory Distress Syndrome
Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
A new artificial lung device has been developed that potentially provides added support to mechanical ventilation for severely damaged lungs.
- Conditions
- Emphysema, Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00288964
- Testing
- Hattler Respiratory Assist Catheter
- Where
- United Kingdom
- Sponsor
- Alung Technologies
Chronic Bronchitis, COPD
Gala Treatment for Chronic Bronchitis in Canada
Feasibility trial (FIH) to assess the safety and clinical utility in patients with chronic bronchitis in Canada.
- Trial name
- NCT03385616
- Testing
- Gala Airway Treatment System
- Where
- 3 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Gala Therapeutics, Inc.
COPD, Exacerbation
A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD
COPD is a major cause of ill health and death in Australia with 40,000 hospital admissions, and a national cost of $898,000,000 annually.
- Trial name
- NCT00446667
- Testing
- mannitol
- Where
- 2 sites in Australia
- Sponsor
- Syntara
COPD (Chronic Obstructive Pulmonary Disease), Intersitital Lung Disease
MoblO2 to Maintain Oxygenation
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course.
- Trial name
- SSeifert (NCT07704567)
- Testing
- MoblO2 controls O2 flow, MoblO2 does not control flow
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Minnesota HealthSolutions